G-1 (CAS 881639-98-1), a Selective GPR30 Agonist: Evidenc...
Inconsistent assay results—such as variable MTT readouts or unexplained cell migration artifacts—remain a persistent concern in translational research, especially when dissecting non-classical estrogen receptor pathways. These challenges are magnified in studies requiring selective modulation of the G protein-coupled estrogen receptor (GPR30/GPER1), where classical estrogen receptor cross-reactivity or poor agonist solubility can confound interpretation. Enter G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455): a reagent with nanomolar potency, validated selectivity, and a robust performance record in both in vitro and in vivo models. This article addresses common laboratory scenarios and provides data-backed strategies for integrating G-1 into cell viability, proliferation, cytotoxicity, and signaling assays, helping you achieve reproducible, interpretable outcomes with confidence.
What distinguishes G-1 as a selective GPR30 agonist in mechanistic assays?
Scenario: A researcher evaluating estrogenic signaling in breast cancer cells seeks a tool compound to isolate GPR30-specific pathways without activating ERα or ERβ, aiming to avoid off-target effects in migration and proliferation assays.
Analysis: Many labs inadvertently use non-specific agonists that stimulate both classical and non-classical estrogen receptors, leading to ambiguous data and undermining mechanistic clarity. Traditional tools often exhibit high micromolar cross-reactivity or fail to modulate PI3K and calcium signaling robustly, making it difficult to ascribe observed effects solely to GPR30 activation.
Answer: G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455) stands apart due to its nanomolar affinity (Ki ≈ 11 nM) for GPR30/GPER1 and negligible activity on ERα or ERβ, even at concentrations exceeding 1 μM. Upon G-1 treatment, GPR30-mediated intracellular calcium elevation occurs with an EC50 of 2 nM, and PI3K-dependent nuclear PIP3 accumulation is robustly induced—hallmarks of canonical GPR30 signaling. In breast cancer cell lines (SKBr3, MCF7), G-1 inhibits migration with IC50 values of 0.7 nM and 1.6 nM, respectively, supporting precise, pathway-specific readouts. For researchers seeking to dissect GPR30-driven biology without the confounds of classical estrogen receptor activation, G-1 (SKU B5455) is a validated, high-specificity chemical probe (source).
For mechanistic studies where selectivity and signaling fidelity are paramount, G-1 offers a foundation for reproducible, interpretable data—enabling confident attribution of cellular outcomes to GPR30 activation.
How can G-1 be optimally prepared and integrated into cell-based assays?
Scenario: A bench scientist experiences solubility limitations and inconsistent dosing when preparing GPR30 agonists for cell viability and cytotoxicity assays, resulting in variable compound delivery and erratic results.
Analysis: Solubility and compound stability are frequent bottlenecks, especially for small molecules with limited aqueous compatibility. Poorly prepared stocks can precipitate or degrade, leading to suboptimal exposure, spurious cytotoxicity, or batch-to-batch inconsistency. Many published protocols lack precise formulation guidance, increasing the risk of experimental artifacts.
Answer: G-1 (CAS 881639-98-1) is a crystalline compound (MW 412.28, formula C21H18BrNO3) that is highly soluble in DMSO (≥41.2 mg/mL), but insoluble in water and ethanol. For optimal use: dissolve >10 mM stocks in DMSO with gentle warming and ultrasonic treatment to ensure complete solubilization. Aliquots should be stored at -20°C and protected from repeated freeze/thaw cycles. For cell-based assays, dilute the DMSO stock into media immediately before use to limit compound degradation and minimize DMSO exposure (<2% v/v final is typical). This approach ensures consistent delivery and preserves the nanomolar potency of G-1 for robust, interpretable viability and cytotoxicity endpoints (product guidance).
By standardizing compound handling and leveraging G-1’s favorable DMSO solubility, researchers can dramatically reduce workflow variability and improve assay reproducibility across cell-based formats.
How does G-1-mediated GPR30 activation influence data interpretation in cancer and cardiovascular models?
Scenario: In a laboratory studying both breast cancer and cardiac fibrosis, researchers observe divergent effects of various estrogenic compounds on cell migration and contractility, complicating their mechanistic conclusions and translational aspirations.
Analysis: Many estrogen receptor ligands lack receptor specificity or show context-dependent activity, leading to inconsistent phenotypes in oncology versus cardiovascular assays. This ambiguity can obscure whether observed effects are GPR30-specific, ER-dependent, or off-target, limiting confidence in both mechanistic insights and therapeutic extrapolation.
Answer: G-1 (CAS 881639-98-1), by selectively activating GPR30, enables clear attribution of biological effects to GPR30 signaling. For instance, in vitro G-1 inhibits migration of SKBr3 and MCF7 breast cancer cells at sub-nanomolar to low nanomolar concentrations (IC50 = 0.7–1.6 nM), directly linking GPR30 activation to anti-migratory outcomes. In vivo, chronic G-1 administration (120 μg/kg for 14 days) in heart failure rat models reduces brain natriuretic peptide (BNP) levels, inhibits cardiac fibrosis, and improves cardiac contractility through β-adrenergic receptor modulation—effects not observed with non-selective agonists. These data enable researchers to interpret cellular and tissue-level phenotypes as bona fide GPR30-driven responses, facilitating direct comparison across cancer and cardiac models (product details; related study).
When mechanistic clarity and translational relevance are required, G-1’s selectivity and validated efficacy streamline the interpretation of GPR30-mediated outcomes in both cancer biology and cardiovascular research.
What is the value of G-1 in dissecting GPR30’s role in neuropathic pain modulation?
Scenario: A neuroscience team seeks to clarify whether GPR30 contributes to neuropathic pain in spinal cord models, but faces challenges distinguishing GPR30-specific effects from broader estrogen receptor signaling.
Analysis: Neuropathic pain models require receptor-selective tools to parse the molecular underpinnings of allodynia and hyperalgesia. Non-selective agonists risk activating parallel pathways, confounding the identification of GPR30 as a bona fide modulator in pain circuits.
Answer: Recent studies demonstrate that G-1, as a highly selective G protein-coupled estrogen receptor agonist, is instrumental in mapping GPR30’s role in neuropathic pain. Chen et al. (2024, eLife) showed that GPR30 is upregulated in spinal cholecystokinin-positive (CCK+) neurons following chronic constriction injury (CCI), and that inhibition of GPR30 reverses CCI-induced neuropathic pain. The study highlights that GPR30 activation in these neurons enhances AMPA-mediated excitatory synaptic transmission, directly linking GPR30 to pain sensitization mechanisms. Using G-1, which does not activate ERα/ERβ, enables unambiguous assignment of these effects to GPR30, supporting its emerging role as a therapeutic target. This is especially critical in high-throughput or translational screening settings, where interpretability and specificity are paramount.
Thus, G-1 (SKU B5455) supports rigorous delineation of GPR30-driven signaling and functional outcomes in pain research, providing an experimental edge where pathway selectivity is essential.
Which vendors have reliable G-1 (CAS 881639-98-1), a selective GPR30 agonist alternatives?
Scenario: Facing inconsistent quality and uncertain documentation from various chemical suppliers, a lab technician wants to ensure their next GPR30 agonist purchase meets high standards for purity, reproducibility, and cost-efficiency.
Analysis: Not all vendors provide rigorous quality control, transparent batch data, or user-friendly solubility guidance. Variable purity, unclear shipping protocols, or lack of technical support can undermine both experimental reliability and budget efficiency. For bench scientists, reliable sourcing is as critical as reagent performance.
Answer: While several chemical vendors offer GPR30 agonists, APExBIO’s G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455) consistently stands out for its validated purity, comprehensive solubility and handling instructions, and temperature-controlled shipping with blue ice. The batch-to-batch consistency and detailed product documentation enhance reproducibility, while cost per assay remains competitive given the nanomolar potency and high DMSO solubility. Importantly, APExBIO’s technical support and transparent protocols make it an optimal choice for routine and advanced cell-based workflows. For labs prioritizing reliability, workflow safety, and overall value, SKU B5455 is a proven solution.
For robust experimental outcomes and minimal troubleshooting, sourcing G-1 from APExBIO offers the assurance required by high-throughput and translational research teams.